Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,119 public trials 2,034 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Completed

Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab

NCT05267054

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations
  • Beijing Friendship Hospital, Capital Medical University Beijing, Beijing Municipality, China
  • Beijing Cancer Hospital Beijing, Beijing Municipality, China
  • Beijing Hospital Beijing, Beijing Municipality, China
  • Zhujiang Hospital of Southern Medical University Guangzhou, Guangdong, China
View all 19 locations
View Trial Details
Completed

A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

NCT02500407

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +17 more
Locations
  • University of California San Diego Moores Cancer Center La Jolla, California, United States
  • Sansum Medical Clinic, Inc. Santa Barbara, California, United States
  • Rocky Mountain Cancer Center Denver, Colorado, United States
  • Yale University School Of Medicine New Haven, Connecticut, United States
View all 35 locations
View Trial Details
Completed

Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT04045795

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • ~Banner MD Anderson Cancer Center Site Number : 8400005 Gilbert, Arizona, United States
  • City of Hope Site Number : 8400002 Duarte, California, United States
  • Gabrail Cancer Center Site Number : 8400001 Canton, Ohio, United States
  • Investigational Site Number : 0360002 Blacktown, New South Wales, Australia
View all 14 locations
View Trial Details
Completed

First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

NCT04000282

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • City of Hope Site Number : 8400002 Duarte, California, United States
  • Dana Farber Cancer Institute Site Number : 8400003 Boston, Massachusetts, United States
  • Mayo Clinic of Rochester Site Number : 8400005 Rochester, Minnesota, United States
  • UNC Chapel Hill Site Number : 8400006 Chapel Hill, North Carolina, United States
View Trial Details

Related conditions